What Johnson & Johnson's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 9 | 28 |
| Total trades | 14 | 142 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 181,232 | 746,856 |
| Disposed | 236,286 | 767,561 |
| Net activity | −55,054 | −20,705 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Schmid Timothy | EVP, WW Chair, MedTech | Sep 02 | Open-market sale · S | −22,527 | $274.74 | −$6.19M | 25,447 |
| Schmid Timothy | EVP, WW Chair, MedTech | Sep 02 | Exercise / conversion · M | +22,527 | $151.41 | +$3.41M | 47,974 |
| Schmid Timothy | EVP, WW Chair, MedTech | Sep 02 | Open-market sale · S | −11,070 | $274.74 | −$3.04M | 25,447 |
| Schmid Timothy | EVP, WW Chair, MedTech | Sep 02 | Exercise / conversion · M | +11,070 | $131.94 | +$1.46M | 36,517 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17 | Open-market sale · S | −15,000 | $263.36 | −$3.95M | 194,451 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17 | Exercise / conversion · M | +15,000 | $115.67 | +$1.74M | 209,451 |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13 | Open-market sale · S | −102,315 | $261.00 | −$26.7M | 275,967 |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13 | Open-market sale · S | −20,976 | $262.00 | −$5.5M | 378,282 |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13 | Exercise / conversion · M | +123,291 | $115.67 | +$14.3M | 399,258 |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 06 | Open-market sale · S | −6,574 | $255.93 | −$1.68M | 16,994 |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 06 | Open-market sale · S | −9,344 | $257.76 | −$2.41M | 23,568 |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 06 | Exercise / conversion · M | +9,344 | $131.94 | +$1.23M | 32,912 |
| Duato Joaquin | CEO and Chairman of the Board | Aug 05 | Open-market sale · S | −6,523 | $258.74 | −$1.69M | 275,967 |
| Duato Joaquin | CEO and Chairman of the Board | Aug 05 | Open-market sale · S | −41,957 | $258.06 | −$10.8M | 282,490 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20 | Open-market sale · S | −23,054 | $251.27 | −$5.79M | 23,003 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20 | Exercise / conversion · M | +11,925 | $131.94 | +$1.57M | 46,057 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20 | Exercise / conversion · M | +11,129 | $129.51 | +$1.44M | 34,132 |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | Jun 11 | Open-market sale · S | −10,000 | $241.15 | −$2.41M | 114,288 |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | Jun 11 | Exercise / conversion · M | +10,000 | $115.67 | +$1.16M | 124,288 |
| Reed John C | EVP, Innovative Medicine, R&D | May 01 | Withheld — tax / exercise cost · F | −11,002 | $229.85 | −$2.53M | 24,911 |
Loading...
